Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2989191 | 0.99 | TSHR (0.49) | TSHRSMN1; SMN2HPGDALDH1A1KMT2A | |
| SCHEMBL5158745 | 0.93 | TSHR (0.44) | TSHRSMN1; SMN2HPGDALDH1A1KMT2A | |
| SCHEMBL2989357 | 0.87 | TSHR (0.46) | TSHRSMN1; SMN2HPGDALDH1A1KMT2A | |
| SCHEMBL2985406 | 0.81 | TSHR (0.54) | TSHRSMN1; SMN2HPGDMAPTHTT | |
| SCHEMBL4867919 | 0.80 | CYP1A2 (0.48) | TSHRALDH1A1KMT2AMAPT | |
| SCHEMBL2985459 | 0.79 | POLB (0.59) | SMN1; SMN2HPGDALDH1A1KMT2AHTT | |
| SCHEMBL2983320 | 0.79 | POLB (0.59) | SMN1; SMN2HPGDALDH1A1KMT2AHTT | |
| SCHEMBL2987472 | 0.78 | NPSR1 (0.48) | TSHRHPGDALDH1A1KMT2AMAPT | |
| SCHEMBL4054566 | 0.77 | GLI1 (0.44) | SMN1; SMN2HPGDALDH1A1KMT2AMAPT | |
| SCHEMBL2972836 | 0.77 | MEN1 (0.50) | SMN1; SMN2HPGDKMT2AMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786328-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2010-08-31 | — | — | US | claimed |
| US-20070281954-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-12-06 | — | — | US | claimed |
| US-7786328-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2010-08-31 | — | — | US | disclosed |
| US-20070281954-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281954-A1 | Cyclohexyl-1,4-diamine compounds | DPYD, PKD1, AOC1 | TSHR 3832/4885SMN1; SMN2 895/4885HPGD 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.